Industries > Pharma > Women’s Health Market Report 2021-2031
Women’s Health Market Report 2021-2031
Forecasts by Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, PCOS). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios
Women’s Health Market-our new study reveals current trends, technological advancements, and predicted revenues
Where the Women’s Health market is heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 230+ page report provides 150+ tables, 150+ charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Women’s Health market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors
– You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.
Report Scope
Global Women’s Health market 2021-2031 is segmented on the basis of Application and Geography.
• Revenue and growth forecasts from 2021 to 2031 for the Global Women’s Health Market by Application:
–Postmenopausal Osteoporosis
– Hormonal Infertility
– Endometriosis
–Contraceptives
–Menopause
–Polycystic Ovary Syndrome (PCOS)
• Revenue and growth forecasts from 2021 to 2031 for the Global Women’s Health Market by Region:
– North America: US, Canada
– Europe: Germany, UK, Italy, France, Spain, Rest of Europe
– Asia-Pacific: China, India, Japan, Australia, Rest of Asia-Pacific
– Latin America: Brazil, Mexico, and Rest of Latin America
– Middle East & Africa: GCC, South Africa, Rest of MEA
• Our study discusses the selected leading companies that are the major players in the Women’s Health industry:
– Allergan
– Bayer Ag
– Merck & Co., Inc.
– Pfizer, Inc.
– Teva Pharmaceutical Industries Ltd.
– Agile Therapeutics
–Amgen, Inc.
– Apothecus Pharmaceutical Corp.
– Astrazeneca
– Blairex Laboratories, Inc.
–Bristol-Myers Squibb Company
–Ferring B.V.
How the Women’s Health Market report helps you
In summary, our 230+ page report provides you with the following knowledge:
– Revenue forecasts to 2031 for each of the above mentioned segments each forecasted at a global and regional level– growth of all segments on regional level helps to understand most lucrative segment.
– Revenue forecasts to 2031 for 5 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.
– Prospects for established firms and those seeking to enter the market– including company profiles for over 10 of the major companies involved in the Women’s Health market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
COVID 19 Impact & Recovery Analysis on the Market
Currently, COVID-19 (Coronavirus) is prevalent across the globe. Many companies are underway to discover a vaccine, or therapeutics which can prevent or cure the COVID-19 virus. According to the World Health Organization, as of 13th September 2020, there were over 28,637,952 confirmed cases of COVID-19, with more than 917,417 deaths, globally.
The COVID-19 disease is continuously disrupting the growth of various markets. However, the immediate effect of the pandemic is different. Some industries will register a drop in demand, various other markets will remain unchanged and display a promising growth opportunities. The healthcare centers, such as hospitals and diagnostic labs, have been investing heavily in maintaining the supply of essential equipment and drugs. Due to lockdown across the globe, people were unable to reach healthcare facilities and non-urgent procedures were advised to put hold which impacted the healthcare industry a lot.
Due to COVID 19 pandemic patients were reluctant in visiting hospitals or clinics for their treatments and preferred virtual doctor visits. Lockdown across the globe due to the pandemic led to the delay of procedures which were not urgent. These factors negatively impacted the women health market for limited period of time. However, slowly the situation is getting back to normal everywhere and the market discussed is expected to increase in future.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Women’s Health market and leading companies. You will find data, trends and predictions.
The Women’s Health Market 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Women’s Health industry.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Women’s Health Market Report 2021-2031: Forecasts by Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, PCOS). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated VISIONGAIN Reports
1.8. About VISIONGAIN
2. Introduction to the Women’s Health Market
2.1. Women’s Health Market Definition
2.2. Application Submarkets Definitions
2.3. Drug Submarkets Definitions
2.4. Mode Submarkets Definitions
3. Women’s Health Market Overview
3.1. Global Women’s Health Market Size and Forecast by Region
3.2. Global Women’s Health Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Occurrence of Long-lasting Health Circumstances among Women
3.3.2. Market Restraints/Challenges
3.3.2.1. Reluctance to Use Contraceptives
3.3.3. Opportunities
3.3.3.1. Developing Markets
3.3.4. Trends
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weaknesses
3.4.3. Opportunities
3.4.4. Threats
3.5. Porter’s Five Forces Analysis
3.5.1. Competitive Rivalry
3.5.2. Supplier Power
3.5.3. Buyer Power
3.5.4. Threat of Substitution
3.5.5. Threat of New Entry
4. Global Women’s Health Market Analysis and Forecast 2021-2031, by Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Hormonal Infertility
4.3. Postmenopausal Osteoporosis
4.4. Endometriosis
4.5. Contraceptives
4.6. Menopause
4.7. Polycystic Ovary Syndrome
4.8. Other Applications
5. Global Women’s Health Market Analysis and Forecast, 2021-2031 by Drug (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.2. Prolia
5.3. Xgeva
5.4. Forteo
5.5. Mirena
5.6. Nuvaring
5.7. Premarin
5.8. Ortho Tri-Cy Lo (28) Forteo
5.9. Evista
5.10. Zometa
5.11. Minastrin 24 Fe
5.12. Actonel
5.13. Pipeline Drugs
6. North America Women’s Health Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Women’s Health Market Size and Forecast byApplication
6.3. North America Women’s Health Market Size and Forecast by Drug
6.4. U.S. Women’s Health Market
6.5. Canada Women’s Health Market
7. Europe Women’s Health Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Women’s Health Market Size and Forecast by Application
7.3. Europe Women’s Health Market Size and Forecast by Drug
7.4. UK Women’s Health Market
7.5. Germany Women’s Health Market
7.6. France Women’s Health Market
7.7. Rest of Europe Women’s Health Market
8. Asia Pacific Women’s Health Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Women’s Health Market Size and Forecast by Application
8.3. Asia Pacific Women’s Health Market Size and Forecast by Drug
8.4. China Women’s Health Market
8.5. India Women’s Health Market
8.6. Japan Women’s Health Market
8.7. Rest of Asia Pacific Women’s Health Market
9. Latin America Women’s Health Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Women’s Health Market Size and Forecast by Application
9.3. Latin America Women’s Health Market Size and Forecast by Drug
9.4. Brazil Women’s Health Market
9.5. Mexico Women’s Health Market
9.6. Rest of Latin America Women’s Health Market
10. MEA Women’s Health Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Women’s Health Market Size and Forecast by Application
10.3. MEA Women’s Health Market Size and Forecast by Drug
10.4. MEA Women’s Health Market Size and Forecast by Mode
10.5. GCC Women’s Health Market
10.6. South Africa Women’s Health Market
10.7. Rest of MEA Women’s Health Market
11. Companies in the Women’s Health Market
11.1. Bayer AG
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2019)
11.1.3.1. Net Revenue
11.1.3.2. Gross Profit
11.1.3.3. Geographical Revenue, 2019
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2019)
11.2. Allergan
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2019)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.3.3. Geographical Revenue, 2019
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2019)
11.3. Merck&Co
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2019)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.3.3. Geographical Revenue, 2019
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2019)
11.4. Pfizer
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2019)
11.4.3.1. Net Revenue
11.4.3.2. Gross Profit
11.4.3.3. Geographical Revenue, 2019
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2019)
11.5. Amgen
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2019)
11.5.3.1. Net Revenue
11.5.3.2. Gross Profit
11.5.3.3. Geographical Revenue, 2019
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2019)
11.6. Agile Therapuetics
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2019)
11.6.3.1. Net Revenue
11.6.3.2. Gross Profit
11.6.3.3. Geographical Revenue, 2019
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2019)
11.7. Ferring Pharmacueticals
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2019)
11.7.3.1. Net Revenue
11.7.3.2. Gross Profit
11.7.3.3. Geographical Revenue, 2019
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2019)
11.8. Mylan N.V
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2019)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.3.3. Geographical Revenue, 2019
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2019)
11.9. Lupin Limited
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2019)
11.9.3.1. Net Revenue
11.9.3.2. Gross Profit
11.9.3.3. Geographical Revenue, 2019
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2019)
11.10. Blairex Laboratories
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2019)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.3.3. Geographical Revenue, 2019
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2019)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated VISIONGAIN Reports
VISIONGAIN Report Sales Order Form
Appendix A
About VISIONGAIN
Appendix B
VISIONGAIN report evaluation form
LIST OF TABLES
Table No 1: Women’s Health Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 2: Women’s Health Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 3: Women’s Health Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 4: Women’s Health Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 5: Women’s Health Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 6: Women’s Health Market Drivers & Restraints 2020
Table No 7: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 8: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 9: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 10: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 11: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 12: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 13: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 14: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 15: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 16: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 17: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 18: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 19: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 20: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 21: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 22: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 23: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 24: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 25: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 26: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 27: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 28: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 29: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 30: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 31: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 32: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 33: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 34: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 35: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 36: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 37: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 38: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 39: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 40: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 41: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 42: Other Applications Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 43: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 44: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 45: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 46: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 47: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 48: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 49: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 50: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 51: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 52: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 53: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 54: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 55: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 56: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 57: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 58: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 59: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 60: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 61: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 62: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 63: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 64: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 65: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 66: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 67: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 68: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 69: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 70: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 71: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 72: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 73: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 74: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 75: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 76: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 77: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 78: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 79: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 80: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 81: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 82: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 83: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 84: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 85: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 86: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 87: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 88: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 89: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 90: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 91: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 92: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 93: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 94: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 95: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 96: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 97: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 98: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 99: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 100: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 101: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 102: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 103: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 104: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 105: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 106: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 107: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 108: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 109: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 110: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 111: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 112: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 113: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 114: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 115: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 116: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 117: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 118: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 119: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 120: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 121: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 122: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 123: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 124: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 125: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 126: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 127: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 128: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 129: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 130: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 131: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 132: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 133: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 134: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 135: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 136: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 137: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 138: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 139: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 140: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 141: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 142: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 143: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 144: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 145: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 146: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 147: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 148: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 149: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 150: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 151: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 152: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 153: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 154: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 155: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 156: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 157: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 158: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 159: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 160: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 161: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 162: Asia Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 163: Asia Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 164: Asia Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 165: Asia Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 166: Asia Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 167: Asia Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 168: Asia Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 169: Asia Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 170: Asia Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 171: Asia Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 172: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 173: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 174: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 175: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 176: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 177: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 178: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 179: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 180: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 181: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 182: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 183: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 184: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 185: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 186: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 187: RoAPAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 188: RoAPAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 189: RoAPAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 190: RoAPAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 191: RoAPAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 192: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 193: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 194: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 195: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 196: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 197: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 198: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 199: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 200: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 201: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 202: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 203: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 204: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 205: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 206: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 207: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 208: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 209: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 210: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 211: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 212: Rest of Latin America Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 213: Rest of Latin America Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 214: Rest of Latin America Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 215: Rest of Latin America Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 216: Rest of Latin America Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 217: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 218: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 219: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 220: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 221: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 222: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 223: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 224: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 225: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 226: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 227: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 228: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 229: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 230: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 231: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 232: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 233: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 234: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 235: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 236: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 237: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 238: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 239: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 240: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 241: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 242: Leading 10 Women’s Health Market Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table No 243: Bayer AG Profile (CEO, HQ, Founded, Website)
Table No 244: Bayer AG (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 245: Bayer AG (Net Income 2016-2019 (US$mn, AGR %)
Table No 246: Allergan Profile (CEO, HQ, Founded, Website)
Table No 247: Allergan (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 248: Allergan (Net Income 2016-2019 (US$mn, AGR %)
Table No 249: Merck & Co. Profile (CEO, HQ, Founded, Website)
Table No 250: Merck & Co. (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 251: Merck & Co. (Net Income 2016-2019 (US$mn, AGR %)
Table No 252: Pfizer Profile (CEO, HQ, Founded, Website)
Table No 253: Pfizer (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 254: Pfizer (Net Income 2016-2019 (US$mn, AGR %))
Table No 255: Amgen Profile (CEO, HQ, Founded, Website)
Table No 256: Amgen (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 257: Amgen (Net Income 2016-2019 (US$mn, AGR %))
Table No 258: Agile Therapuetics Profile (CEO, HQ, Founded, Website)
Table No 259: Agile Therapuetics (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 260: Agile Therapuetics (Net Income 2016-2019 (US$mn, AGR %))
Table No 261: Ferring Pharmacueticals Profile (CEO, HQ, Founded, Website)
Table No 262: Ferring Pharmacueticals (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 263: Ferring Pharmacueticals (Net Income 2016-2019 (US$mn, AGR %))
Table No 264: Mylan N.V. Profile (CEO, HQ, Founded, Website)
Table No 265: Mylan N.V. (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 266: Mylan N.V. (Net Income 2016-2019 (US$mn, AGR %))
Table No 267: Lupin Limited. Profile (CEO, HQ, Founded, Website)
Table No 268: Lupin Limited. (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 269: Lupin Limited.(Net Income 2016-2019 (US$mn, AGR %))
Table No 270: Blairex Laboratories. Profile (CEO, HQ, Founded, Website)
Table No 271: Blairex Laboratories. (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 272: Blairex Laboratories.(Net Income 2016-2019 (US$mn, AGR %))
Table No 273: Other Companies Women’s Health Market 2020 (Company, Location)
LIST OF FIGURES
Figure No 1: Women’s Health Market Application Overview
Figure No 2: Women’s Health Market Drug Overview
Figure No 3: Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 4: Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 5: Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 6: Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 7: Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 8: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure No 9: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure No 10: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure No 11: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure No 12: Women’s Health Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure No 13: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 14: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 15: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 16: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 17: Hormonal Infertility Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 18: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 19: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 20: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 21: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 22: Postmenopausal Osteoporosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 23: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 24: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 25: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 26: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 27: Endometriosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 28: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 29: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 30: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 31: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 32: Contraceptives Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 33: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 34: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 35: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 36: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 37: Menopause Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 38: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 39: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 40: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 41: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 42: Polycystic Ovary Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 43: Other Applications Syndrome Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 44: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 45: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 46: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 47: Other Applications Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 48: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure No 49: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure No 50: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure No 51: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure No 52: Women’s Health Forecast by Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure No 53: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 54: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 55: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 56: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 57: Prolia Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 58: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 59: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 60: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 61: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 62: Xgeva Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 63: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 64: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 65: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 66: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 67: Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 68: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 69: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 70: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 71: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 72: Mirena Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 73: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 74: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 75: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 76: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 77: Nuvaring Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 78: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 79: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 80: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 81: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 82: Premarin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 83: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 84: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 85: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 86: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 87: Ortho Tri-Cy Lo (28) Forteo Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 88: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 89: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 90: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 91: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 92: Evista Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 93: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 94: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 95: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 96: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 97: Zometa Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 98: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 99: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 100: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 101: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 102: Minastrin 24 Fe Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 103: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 104: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 105: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 106: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 107: Actonel Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 108: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 109: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 110: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 111: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 112: Pipeline Drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 113: Regional Women’s Health Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure No 114: Regional Women’s Health Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure No 115: Regional Women’s Health Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure No 116: Regional Women’s Health Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure No 117: Regional Women’s Health Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure No 118: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 119: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 120: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 121: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 122: North America Women’s Health Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 123: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %)
Figure No 124: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 125: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 126: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 127: North America Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 128: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 129: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 130: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 131: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 132: US Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 133: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %)
Figure No 134: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 135: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 136: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 137: Canada Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 138: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M) (Before COVID)
Figure No 139: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 140: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 141: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 142: Europe Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 143: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %)
Figure No 144: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 145: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 146: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 147: Europe Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 148: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 149: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 150: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 151: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 152: UK Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 153: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %)
Figure No 154: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 155: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 156: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 157: Germany Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 158: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %)
Figure No 159: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 160: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 161: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 162: France Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 163: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 164: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 165: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 166: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 167: Rest of Europe Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 168: Asia-Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M) (Before COVID)
Figure No 169: Asia-Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 170: Asia-Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 171: Asia-Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 172: Asia-Pacific Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 173: Asia-Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %)
Figure No 174: Asia-Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 175: Asia-Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 176: Asia-Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 177: Asia-Pacific Women’s Health Market Forecast by Drug 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 178: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %)
Figure No 179: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 180: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 181: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 182: China Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 183: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %)
Figure No 184: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 185: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 186: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 187: India Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 188: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 189: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 190: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 191: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 192: Japan Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 193: Rest of APAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 194: Rest of APAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 195: Rest of APAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 196: Rest of APAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 197: Rest of APAC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 198: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M)
Figure No 199: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 200: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 201: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 202: Latin America Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 203: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M)
Figure No 204: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario V)
Figure No 205: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario U)
Figure No 206: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario W)
Figure No 207: Latin America Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario L)
Figure No 208: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 209: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 210: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 211: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 212: Brazil Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 213: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 214: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 215: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 216: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 217: Mexico Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 218: Rest of Latin America Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 219: Rest of Latin Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 220: Rest of Latin Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 221: Rest of Latin Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 222: Rest of Latin Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 223: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M) (Before COVID)
Figure No 224: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 225: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 226: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 227: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 228: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M) (Before COVID)
Figure No 229: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario V)
Figure No 230: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario U)
Figure No 231: Middle East Women’s Health Market Forecast by Drug 2021-2031 (US$M) (COVID - Scenario W)
Figure No 232: Middle East Women’s Health Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 233: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 234: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 235: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 236: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 237: GCC Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 238: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 239: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 240: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 241: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 242: South Africa Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 243: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 244: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 245: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 246: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 247: Rest of MEA Women’s Health Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 248: Bayer AG (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 249: Bayer AG (Net Income 2016-2019 (US$mn, AGR %)
Figure No 250: Allergan (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 251: Allergan (Net Income 2016-2019 (US$mn, AGR %)
Figure No 252: Merck & Co (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 253: Merck & Co (Net Income 2016-2019 (US$mn, AGR %)
Figure No 254: Pfizer (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 255: Pfizer (Net Income 2016-2019 (US$mn, AGR %))
Figure No 256: Amgen (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 257: Amgen (Net Income 2016-2019 (US$mn, AGR %))
Figure No 258: Agile Therapuetics (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 259: Agile Therapuetics (Net Income 2016-2019 (US$mn, AGR %))
Figure No 260: Ferring Pharmacueticals (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 261: Ferring Pharmacueticals (Net Income 2016-2019 (US$mn, AGR %))
Figure No 262: Mylan N.V. (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 263: Mylan N.V. (Net Income 2016-2019 (US$mn, AGR %))
Figure No 264: Lupin Limited. (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 265: Lupin Limited. (Net Income 2016-2019 (US$mn, AGR %))
Figure No 266: Blairex Laboratories. (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 267: Blairex Laboratories. (Net Income 2016-2019 (US$mn, AGR %))
Companies Profiled in the Report
1. Allergan
2. Bayer Ag
3. Merck & Co., Inc.
4. Pfizer, Inc.
5. Teva Pharmaceutical Industries Ltd.
6. Agile Therapeutics
7. Amgen, Inc.
8. Apothecus Pharmaceutical Corp.
List of Companies Mentioned in the Report:
1. Eli Lilly and Company
2. Johnson & Johnson Services Inc.
3. Novartis AG
4. Mylan NV
5. Lupin Limited
6. Agile Therapeutics
7. Ferring Pharmaceuticals
8. Blairex Laboratories, Inc.
9. Apothecus Pharmaceutical Corporation
10. Allergan
11. Bayer Ag
12. Merck & Co., Inc.
13. Pfizer, Inc.
14. Teva Pharmaceutical Industries Ltd.
15. Agile Therapeutics
16. Amgen, Inc.
17. Apothecus Pharmaceutical Corp.
18. Astrazeneca
19. Blairex Laboratories, Inc.
20. Bristol-Myers Squibb Company
21. Ferring B.V.
List of Organizations Mentioned in the Report:
• Food and Drugs Administration
• American Cancer Society
• World Health Organization
• American Hospital Association (AHA)
• National Cancer Institute
• NIH
• CDC
• Mayo Clinic
Download sample pages
Complete the form below to download your free sample pages for Women’s Health Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Women’s Health Market Report 2021-2031Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
14 September 2023
Visiongain Publishes Stem Cell Therapy Contract Manufacturing Market Report 2023-2033
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
13 September 2023
